Ferronova signs licensing agreement with Purdue Research Foundation (PRF)
Great news! Portfolio company Ferronova recently signed a licensing agreement with with Purdue Research Foundation (PRF). This collaboration will combine Ferronova’s patented FerroTrace® platform with PRF’s patented FAP inhibitor for use in targeted radiotherapy of difficult cancers.
To read more on this announcement, visit https://lnkd.in/gXrkUpG8